The Priority Review

Tag

Beeline Medicines Corporation

1 story

  1. Clinical trials

    Beeline registers Phase 2/3 study of afimetoran in cutaneous lupus erythematosus

    The study, led by Beeline Medicines Corporation, plans to enroll 390 participants and begin in October 2026. It evaluates afimetoran versus placebo over 24 weeks, with a total treatment period of 52 weeks, and aims to assess changes in the CLASI-A skin activity score.